Moderna, Novavax shares dip as CDC panel suggests limiting COVID shot updates

Investing.com -- Shares of vaccine manufacturers Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) experienced slight declines in early trading on Wednesday, with Moderna down 1% and Novavax falling 1.3%.

This comes as an external panel of experts to the U.S. Centers for Disease Control and Prevention (CDC) proposed a change in vaccination recommendations on Tuesday.

The panel suggested that updated COVID-19 shots should only be given to those at risk of severe disease.

If adopted, this would be a shift from the current CDC guidelines, which recommend everyone aged six months and older receive an updated COVID-19 shot.

The proposal by the panel is still under consideration and the CDC has yet to officially change its guidelines.

The potential change could impact the demand for vaccines produced by companies like Moderna and Novavax.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.NVAX: A Bull or Bear Market Play?

Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year..In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies.So if NVAX is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Unlock ProPicks now